Brought to you by 
Alcobra nets $35.7mm in secondary offering to support late-stage studies of MG01CI
06 Nov 2013
Executive Summary
Five months after closing its US IPO, Israeli neurology company Alcobra Ltd. netted $35.7mm in a follow-on public offering of 2.3mm shares (including the overallotment) for $16.50. Alcobra will use approximately $14mm of the proceeds to fund late-stage clinical trials of MG01CI (extended-release metadoxine) for Fragile X syndrome, and $10mm will be allocated to the Phase III program for the same candidate in ADHD.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alcobra nets $35.7mm in secondary offering to support late-stage studies of MG01CI
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice